Biotechnology company Xoma Ltd, based in California, have announced that its experimental diabetes drug Xoma-052 has failed in a clinical trial to reduce levels of blood sugar in diabetes patients .
The study, which involved testing of 421 type 2 diabetes patients with monthly injections of Xoma-052 or a placebo for a period of six months, found that the treatment was not able to reduce levels of blood sugar any more than a placebo, which was the primary goal of the research. However, it did manage to lower levels of c-reactive protein, which is associated with a risk of heart attack or stroke, and the biotech firm hopes to soon expand clinical trials of the drug for these conditions.
The trials showed that levels of ‘good cholesterol ’ were raised in two sets of patients who took the Xoma drug, a finding that may suggest the drug could be useful for treating heart disease, as well as Behcet’s uveitis, a condition that causes eye inflammation .
Steven B. Engle, chief executive officer of Xoma, commented “While this trial did not demonstrate glycemic improvement, the potent anti-inflammatory effects and continued positive safety profile reinforce our Phase 3 development program for Behcet’s uveitis, which we anticipate starting this year.”

Get our free newsletters

Stay up to date with the latest news, research and breakthroughs.

You May Also Like

Coronavirus: UK instructed to stay at home this weekend

Health Secretary Matt Hancock has said that staying at home this weekend…

Public Health England considers low carb approach for type 2 diabetes

The low carb approach is being considered by the government to be…

Twice daily dairy intakes could reduce type 2 diabetes risk

Eating cheese, yoghurt or eggs twice a day could help lower the…